Abstract:To retrospectively investigate the feasibility of radiofrequency ablation (RFA) in treating advanced hepatocellular carcinoma (HCC) using standard ultrasound-guided percutaneous RFA.A total of 655 patients with unresectable advanced HCC underwent ultrasound-guided percutaneous RFA therapy at our institution between July 2000 to September 2001. Ninety-two of those patients, representing 136 tumors, were selected for analysis based on the following criteria: presence of UICC/AJCC-TNM (6th edition) stage III and IV advanced HCC, (III: n=82 patients, with 126 tumors; IV: n=10 patients, with 10 tumors); extensive portal vein or inferior vena cava tumor thrombus; extrahepatic metastasis after surgical resection; and complete follow-up data. Follow-up consisted of enhanced computed tomography (CT) performed at one month post-RFA treatment, then every three months. Contrast-enhanced ultrasound (CEUS) was performed in 51 (55.4%) patients before RFA. The standard treatment using optimal strategies were applied in (72.8%) 67 patients. The established strategies included: (1) select RFA indications based on CEUS results; (2) design radical protocols based on invasive range showed by CEUS; (3) multiple overlapping ablations based on mathematical protocols; (4) two or three bipolar RFA electrodes with three-dimensional localization; (5) color ultrasound-guided percutaneous ablation of tumor feeding artery (PAA)/transcatheter arterial chemoembolization (TACE) + RFA for HCC with rich supply. The other 25 patients (27.2 %) were treated with conventional RFA protocols. The ablation procedure was considered a success if no abnormal enhancement or wash-out was detected in the treated area on the CT scan at one month. All patients had received liver protection treatments following RFA. Chi-squared test or Fisher's exact test were used to compare the early complete tumor necrosis rates and the local recurrence rates. Survival was estimated by Kaplan-Meier analysis and log-rank test. P less than 0.05 was considered statistically significant.The RFA-treated tumors ranged in size from 1.5 to 7.0 cm (average: 4.5 cm). Fifty-nine patients had solitary tumor, and the remaining 33 had multiple tumors (2 to 4 tumors). Patients were classified by Child-Pugh score as A (n=58), B (n=32) and C (n=2). Early complete tumor necrosis rate after initial RFA was 90.4% (123/136 tumors). Serious complications developed in two patients (2.2%). No treatment-related death occurred. Follow-up ranged from 3-134 months. Local recurrence rate was 16.9% (23/136 tumors). The 1-, 3- and 5-year overall survival rates were 83.3%, 48.3% and 21.9%, respectively, and the median survival time was 35 months. Stratification analysis indicated the early complete tumor necrosis rate was higher in groups of patients with Child-Pugh A score (98.3%) , CEUS administration (98.0%), and standard treatment (97.0%). The local recurrence rate was lower in groups of patients with tumors less than or equal to 3.0 cm (5.9%), CEUS administration (11.8%), and standard treatment (16.4%). The 5-year survival was significantly higher in patients with Child-Pugh A, tumors less than or equal to 3.0 cm, CEUS administration, and standard treatment (all, P less than 0.05).RFA treatment of patients with advanced HCC, tumors less than 7.0 cm, and without thrombosis in the main vessels was efficacious. The RFA treatment strategy and subsequent liver protection therapy in RFA may improve survival.

Efficacy of radiofrequency ablation vs. transcatheter arterial embolization for hepatic hemangiomas

Surgical Resection Plus Radiofrequency Ablation for the Treatment of Multifocal Hepatocellular Carcinoma.

Radiofrequency Ablation for Treatment of Giant Hepatic Hemangiomas

Laparoscopic vs computerized tomography-guided radiofrequency ablation for large hepatic hemangiomas abutting the diaphragm

[The New Technology of Enhanced Radiofrequency Ablation is Safe and Effective for Treating Giant Hepatic Hemangioma].

Radiofrequency Ablation Following First-Line Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma Beyond the Milan Criteria

[Efficacy of Radiofrequency Ablation of 343 Patients with Hepatic Tumor and the Relevant Complications].

Elimination Rate Of Tumor'S Blood Supply, Tumor Necrosis Rate And Adverse Reactions In Advanced Hepatocellular Carcinoma Treated By Transcatheter Arterial Chemoembolization With Radiofrequency Ablation

Radiofrequency Ablation is Superior to Ethanol Injection in Early-Stage Hepatocellular Carcinoma Irrespective of Tumor Size.

Thermal Ablation of Hepatic Hemangioma: A Multi-Center Experience with Long-Term Outcomes

Combination of transcatheter arterial chemoembolization and radiofrequency ablation in hepatocellular carcinoma treatment

[Feasibility of Improving Radiofrequency Ablation of Hepatocellular Carcinoma by Percutaneously Blocking Tumor-Feeding Vessels].

Treatment Efficacy of Radiofrequency Ablation of 338 Patients with Hepatic Malignant Tumor and the Relevant Complications.

Efficacy of radiofrequency ablation to treat advanced hepatocellular carcinoma]

Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma

Survival of Patients Receiving Radiofrequency Ablation or Ethanol Injection for Early-Stage Hepatocellular Carcinoma.

Comparison Of Long-Term Effectiveness And Complications Of Radiofrequency Ablation With Hepatectomy For Small Hepatocellular Carcinoma

Radiofrequency Ablation Combined with Transarterial Chemoembolization for Treating of Hepatic Metastases

Long-term Outcomes of Combined Transarterial Chemoembolization and Radiofrequency Ablation Versus RFA Monotherapy for Single Hepatocellular Carcinoma ≤3 Cm: Emphasis on Local Tumor Progression

Transcatheter Arterial Embolization Alone for Giant Hepatic Hemangioma

The Efficacy of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Primary Hepatocellular Carcinoma in a Cohort of 487 Patients